Oxford Asset Management’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Oxford Asset Management’s Portfolio NVLN Stock Details NVLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-42,808	Closed	-$138K	–	2027
2017 Q4	$138K	Buy	42,808 +14,211	+50%	+$68.3K	﹤0.01%	1502
2017 Q3	$201K	Sell	28,597 -22,572	-44%	-$181K	﹤0.01%	1423
2017 Q2	$472K	Sell	51,169 -64,141	-56%	-$618K	0.01%	1133
2017 Q1	$1.24M	Buy	+115,310	New	+$1.18M	0.03%	716

Other funds holding NVLN

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return

HVC

Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Oxford Asset Management's NVLN Position: Q1 2018 in Review

Oxford Asset Management sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q1 2018, closing a stake of 42,808 shares — an estimated $138K sold.

Oxford Asset Management first reported a position in NVLN in Q1 2017 and held it in 4 quarters. The position peaked at $1.24M in Q1 2017. 68 funds tracked by Wall St. Rank hold NVLN as of Q1 2018.

Oxford Asset Management reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q1 2018 after selling out during the quarter.
Oxford Asset Management sold 42,808 Novelion Therapeutics Inc. Common Shares shares in Q1 2018, an estimated $138K.
Oxford Asset Management first reported a position in Novelion Therapeutics Inc. Common Shares in Q1 2017 and held it in 4 quarters.
Oxford Asset Management's Novelion Therapeutics Inc. Common Shares position peaked at $1.24M in Q1 2017.
68 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q1 2018.

Based on Oxford Asset Management's 13F filing for Q1 2018, filed 15 May 2018.